Laurus Labs

Most of the climb came in the last four months. The share closed at ₹1,517.40 at the end of June.

• It hit its low of ₹930.20 on 1 February 2026.
• It reached its high of ₹2,405.50 on 30 October, the day after the Jul–Sep results, jumping from ₹2,244 to ₹2,405.50 in a single day.
• It is now 2.4% below that high.

The share has moved with the profit. From here, the profit has to keep pace with the price.

The loans are paying for new plants, not covering losses. Counting its cash against it, the debt is about one year of operating profit, down from 1.28 years three months earlier, the CFO said. In Jul–Sep, interest took ₹44 crore out of ₹750 crore of operating profit.

CARE Ratings reaffirmed its AA rating in July. One of the triggers it lists for a downgrade is debt going beyond 2.75 times a year's operating profit. Laurus is at about one.

The company chose this route on purpose, preferring growth to free cash:

we have taken a call between the free cash flow versus the growth capital, and then we are investing growth capex.

V. V. Ravi Kumar, CFO, Jul–Sep 2026 call

Expect the debt to stay while the plants go up. At today's profit, it is comfortable.

Measured from FY21, profit is still 2% a year lower, by CAGR. Sales grew 7% a year over the same five years. The last six months alone earned ₹809 crore, almost all of FY26's profit.

An investor on the call put it simply:

The numbers are finally catching up with the work you have been doing for years, well deserved.

Sajal Kapoor, Antifragile Thinking, on the Jul–Sep 2026 call

The slump is behind it. FY27 is on course to be the first year profit passes FY21.

Two things lifted it. The mix: the company credits the bigger share of CDMO work, which leaves more of each sale as profit. Gross margin, what is left after raw materials, rose to 63% from 59.9%. Scale: the plants run fuller, so the fixed costs are spread over more sales.

One part is timing. Research spending fell to ₹65 crore in Jul–Sep, after a heavier Apr–Jun, when Laurus filed applications to sell new generic drugs in the US. The CFO was clear it is not a cut:

I think the quarter 1, we have filed some ANDAs. So there is a reason the cost has gone up in quarter 1. It is not that we are defocusing on our R&D expenditure.

V. V. Ravi Kumar, CFO, Jul–Sep 2026 call

Margins this high rest on CDMO staying strong. The company's own floor is 30%.

From FY21 to FY25, spending matched or beat the cash coming in every year, and borrowings rose from ₹1,482 crore to ₹2,764 crore. FY26 was the turn: operations brought in far more than went out, and borrowings fell to ₹2,518 crore. Asked about it on the call, the finance head said:

yes, last year only we have a free cash flow when you are making that kind of a capex investment

V. V. Ravi Kumar, CFO, Jul–Sep 2026 call

Apr–Sep 2026 swung back. Operating cash fell to ₹805 crore, from ₹1,093 crore, as Laurus built up stock, while ₹864 crore went into plants. The CFO called it regular inventory that will be used in the coming quarter.

Laurus waits about 115 days to be paid (debtor days) and holds stock for about 125 days (inventory days), on FY26 figures.

The profit is real cash; the building spends it. Watch Oct–Dec 2026 for the stock turning back into cash.

Five directors work in the company and five are independent.

The founder was paid 491 times the median employee's pay in FY26, up 89% on the year. The annual report puts the rise down to a larger bonus as results improved. The median employee's pay rose 5%.

Asked what could break Laurus's run, he spoke of turning work away rather than letting customers down:

Business will not come today, it will come tomorrow. So we don't want to spoil partnerships or relationships by taking too much that we cannot handle.

Dr Satyanarayana Chava, founder and CEO, Jul–Sep 2026 call

The one thing the auditor looked at hardest was sales near the year end: whether goods booked in the last days of March had really reached the customer. That is a routine check for an exporter, not a finding.

Laurus has also guaranteed ₹674 crore of bank loans taken by its own subsidiaries. Those loans are already counted in its debt.

A clean report.

The founder is frank about why no one customer dominates:

Currently, we don't have a significant concentration of customers or programs. We are managing -- actually, we are not managing. We were lucky that the projects are coming like that.

Dr Satyanarayana Chava, founder and CEO, Jul–Sep 2026 call

CARE also names the usual risks for a drug exporter: regulators abroad, and swings in the rupee.

The near-term risk is uneven quarters. The long-term bet is peptides.

Foreign funds now own more of Laurus than its promoters do. FIIs rose to 30.8%, while DIIs fell to 11.9%.

The two largest named foreign holders, both run by the American firm Capital Group, cut their stakes: New World Fund to 3.53% from 4.28%, and SmallCap World Fund to 2.26% from 2.77%. So the buying came from other foreign funds. Vanguard's international index fund now holds 1.0%.

Small investors kept coming. Shareholders rose from 2,91,653 to 3,11,892 in three months.

Foreign money is following the results. Indian funds sold some.